YSYu Shi

Yu Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu Shi has a total of 409 co-authors. Here are the top co-authors by number of shared publications:

  • Xiu-Wu Bian

    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University), and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China

    20 shared publications
  • Yi-Fang Ping

    Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University) Chongqing PR China

    16 shared publications
  • Qing Liu

    Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University) Chongqing PR China

    12 shared publications
  • Min Mao

    Institute of Pathology & Southwest Cancer Center, the First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences Army Medical University (Third Military Medical University), and the Key Laboratory of Tumor Immunopathology, the Ministry of Education (Third Military Medical University) Chongqing PR China

    9 shared publications
  • Cong Chen

    Intelligent Pathology Institute, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China

    8 shared publications
  • Min Luo

    Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology, Ministry of Education of China, Chongqing, China

    8 shared publications

Latest Publications

  • The spatiotemporal evolution of radiation resistance in glioblastoma

    by Lingxiang Wu, Lei Cheng, Bin Huang, Runheng Huang, Ravesanker Ezhilarasan, Junxia Zhang, Wei Wu, Guojing Wu, Benqing Yu, Lindsey D Goodman, et al.

    Background: Although radiation therapy (RT) remains one of the most effective treatments for patients with the lethal brain tumor glioblastoma (GBM), quite a number of patients show resistance or relapse shortly after RT. There is an urgent need to uncover the temporal and spatial dynamics of RT resistance during tumor progression and treatment. Methods: The radio-resistance signature score (RRSS) was calculated by utilizing glioma sphere-forming cells (GSCs), which recapitulate the transcriptomic landscape of GBM. Results: RRSS can assess the RT response on both cell lines and GBM patients. Both transdifferentiated and irradiated glioma cells show increased radiation resistance, demonstrating that the recurrent GBM may acquire resistance along with cell differentiation and selective advantage during treatment. Moreover, RRSS of the marginal tumors is found to be higher than that of core tumors (Wilcoxon’s rank-sum test, P-value <.01). The infiltration of macrophages was significantly associated with radiation resistance (P-value <.01), which was further validated by single-cell RNAseq-based experiments and clonogenic assays. Moreover, we demonstrated that IL1B, a pro-inflammatory cytokine secreted by macrophages, could enhance the radiation resistance of tumor cells. Conclusions: Our study revealed the spatiotemporal evolution of radiation resistance of GBM and shed light on the development of novel adjuvant therapeutic strategies.


  • Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target

    by Xiang Fang, Fanqi Wang, Haiman Li, Ping Xiao, Mengru Wang, Nan Wu, Xiaohong Yao, Yu Shi


  • Human induced pluripotent stem cell‐derived chimeric antigen receptor‐macrophages eradicate IL ‐ 13Rα2 ‐positive solid tumors

    by Ying Yang, Lujing Wang, Yi Zhang, Shuzhen Lyu, Qianying Ruan, Chao Wang, Feiyue Dou, Gongbo Liang, Guangning Yan, Mengru Wang, et al.

    Macrophages exhibit extensive tumor infiltration capacity across diverse solid malignancies, establishing macrophage‐targeted immunotherapies as an emerging frontier in oncology. Genetic engineering of macrophages using chimeric antigen receptor (CAR) technology − enabling recognition and phagocytosis of neoplastic cells − is emerging as a potential therapeutic strategy against solid tumors. Human induced pluripotent stem cells (iPSCs) provide a renewable platform for the efficient differentiation of functionally competent macrophages. In this study, we engineered human iPSC‐derived CAR macrophages (iCAR‐M) targeting interleukin‐13 receptor subunit alpha 2 (IL‐13Rα2). Pan‐tumor transcriptomic and immunohistochemical analyses revealed that IL‐13Rα2, a tumor‐associated antigen, was overexpressed in human glioblastoma (GBM), uterine carcinosarcoma (UCS), and melanoma specimens. In vitro phagocytosis assays revealed target‐specific clearance of IL‐13Rα2‐positive tumor cells by iCAR‐M. Intracranial administration of iCAR‐M potently suppressed tumor growth, enhanced intratumoral cytotoxic T‐cell infiltration, and prolonged the survival of humanized, immunocompetent mice bearing GBM xenografts. The administered iCAR‐M maintained phagocytic capacity in vivo and acquired an M1‐like pro‐inflammatory phenotype. Comprehensive safety assessment revealed no detectable evidence of systemic toxicity or treatment‐related neurotoxicity. Collectively, these results demonstrate the potent efficacy and favorable safety profile of iPSC‐derived, IL‐13Rα2‐targeted CAR macrophages, supporting their therapeutic potential against solid tumors. © 2026 The Pathological Society of Great Britain and Ireland.


  • Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors

    by Yue Cheng, Tianran Li, Mengru Wang, Chuan Lan, Haizhen Fan, Zhicheng He, Qing Liu, Fei Li, Lujing Wang, Wenying Wang, et al.

    Both primary and metastatic brain malignancies are fatal and highly infiltrated with tumor-associated macrophages (TAMs). Enhancing the phagocytosis of neoplastic cells by TAMs is pivotal for slowing tumor growth. Great endeavors have been made to develop tyrosine kinase inhibitors (TKIs) for brain malignancies, yet whether tumor-targeting TKIs affect the phagocytic capacity of TAMs remains largely unknown. In this preclinical study, we report that repurposing ibrutinib, a blood-brain barrier–penetrable TKI, effectively suppresses the growth of several primary and metastatic brain tumors highly expressing Bruton’s tyrosine kinase (BTK) or bone marrow X-linked nonreceptor tyrosine kinase (BMX) but concurrently dampens the TAM phagocytic function. Mechanistically, BTK, which is activated in TAMs, interacts with and phosphorylates Wiskott-Aldrich syndrome protein (WASp) to organize the actin cytoskeleton, which is imperative for phagocytosis. Ibrutinib treatment disrupts BTK-mediated WASp activation, thereby compromising TAM phagocytic efficacy. Pharmacological activation of WASp by its selective small-molecular activator EG-011 restores the ibrutinib-impaired TAM engulfment of tumor cells and effectively improves ibrutinib efficacy in mice bearing glioblastomas, primary central nervous system lymphomas, and lung carcinoma brain metastases. Furthermore, elevated expression of phosphorylated BTK or phosphorylated WASp in TAMs correlates with an increased phagocytic TAM subset identified by single-cell RNA sequencing and correlates with prolonged patient survival in a cohort with glioblastoma. Our preclinical study highlights the necessity of evaluating the on-target, off-tumor attack of TAMs during TKI administration and provides a proof of concept for reinvigorating the TAM phagocytic function to achieve additional clinical benefit.


  • Fluid shear stress activates a targetable mechano-metastatic cascade to promote medulloblastoma metastasis

    by Hyun-Kee Min, Hongyu Zhao, Alexander Bahcheli, Peng Pan, Jade Chan, Junsheng Chen, Esther Low, Yuxiao Zhou, Xian Wang, Savo Bajic, et al.

    Biofluid flow generates fluid shear stress (FSS), a mechanical force widely present in the tissue microenvironment. How brain tumour growth alters the conduit of biofluid and impacts FSS-regulated cancer progression is unknown. Dissemination of medulloblastoma (MB) cells into the cerebrospinal fluid initiates metastasis within the central nervous system. Here, by simulating cerebrospinal fluid dynamics based on magnetic resonance imaging of patients with MB, we discover that FSS is elevated at the cervicomedullary junction. MB-relevant FSS promotes metastasis along the mouse spinal cord. Mechanistically, FSS induces metastatic cell behaviours, including weakened cell-substrate adhesion, increased motility, cell clustering and plasma membrane localization of glucose transporter 1 (GLUT1) to enhance glucose uptake. FSS is perceived by the mechanosensitive ion channel PIEZO2, which drives actomyosin contractility-dependent GLUT1 recruitment at the plasma membrane. Genetic targeting of PIEZO2 or pharmacologic inhibition of GLUT1 mitigates metastasis. Collectively, these findings define a targetable FSS-activated mechano-metastatic cascade for the treatment of MB metastasis.


  • Open Access

    Harnessing chimeric antigen receptor macrophages against solid tumors

    by Mengru Wang, Zhen Qin, Xiu‐Wu Bian, Yu Shi

    Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen receptors (CARs) to endow macrophages with anti‐tumor capacities demonstrated encouraging efficacy, particularly in enhancing tumor‐targeted phagocytosis. Furthermore, CAR macrophages (CAR‐Ms) orchestrate adaptive immunity through secreting pro‐inflammatory cytokines and presenting tumor antigens, thereby activating cytotoxic T lymphocyte responses. These multifaceted properties establish CAR‐Ms as potent immunotherapeutic agents against therapy‐refractory solid malignancies. Herein, we delineate the design principles, recent research advances, and rational combination strategies of CAR‐Ms, with particular emphasis on emerging clinical evidence from ongoing CAR‐M trials. We also explore potential applications of CAR‐Ms in non‐tumorous diseases and forecast future trends based on CAR‐T therapy evolution. CAR‐M development, combined with emerging technologies, will generate new perspectives for advancing cancer immunotherapy.


  • Open Access

    Cd248a regulates pericyte development and viability in zebrafish

    by Chao Wang, Yinming Zhong, Yi Zhang, Yiyang Jiang, Chenshiyu Wang, Lele An, Chunhua Luo, Lan Yang, Zhicheng He, Ying Yang, et al.

    CD248 is a pericyte marker during embryonic and tumor neovascularization. Although its expression pattern and function in mammalian pericytes have been extensively studied, its role in zebrafish pericytes remains largely unexplored. In this study, we identify that among the two zebrafish orthologs of human CD248, cd248a, rather than cd248b, is predominantly expressed in pericytes during embryonic development. We generate cd248a and cd248b mutant zebrafish (cd248acc11/cc11 and cd248bcc12/cc12) and observe a significant reduction in pericyte numbers in cd248acc11/cc11 mutants, accompanied by disruption of the blood-brain barrier. Notably, treatment with AG1295, a platelet-derived growth factor receptor inhibitor, attenuates the increase in pericyte proliferation induced by cd248a overexpression. Additionally, we find that CoCl2-induced pericyte apoptosis is enhanced in cd248acc11/cc11 larvae, indicating that cd248a provides protection against hypoxia-induced apoptosis. Taken together, our findings elucidate the role and underlying mechanisms of cd248a in regulating pericyte proliferation and apoptosis in zebrafish.


  • A peptide encoded by upstream open reading frame of MYC binds to tropomyosin receptor kinase B and promotes glioblastoma growth in mice

    by Fanying Li, Kailin Yang, Xinya Gao, Maolei Zhang, Danling Gu, Xujia Wu, Chenfei Lu, Qiulian Wu, Deobrat Dixit, Ryan C. Gimple, et al.

    MYC promotes tumor growth through multiple mechanisms. Here, we show that, in human glioblastomas, the variant MYC transcript encodes a 114–amino acid peptide, MYC pre-mRNA encoded protein (MPEP), from the upstream open reading frame (uORF) MPEP . Secreted MPEP promotes patient-derived xenograft tumor growth in vivo, independent of MYC through direct binding, and activation of tropomyosin receptor kinase B (TRKB), which induces downstream AKT-mTOR signaling. Targeting MPEP through genetic ablation reduced growth of patient-derived 4121 and 3691 glioblastoma stem cells. Administration of an MPEP-neutralizing antibody in combination with a small-molecule TRKB inhibitor reduced glioblastoma growth in patient-derived xenograft tumor–bearing mice. The overexpression of MPEP in surgical glioblastoma specimens predicted a poor prognosis, supporting its clinical relevance. In summary, our results demonstrate that tumor-specific translation of a MYC -associated uORF promotes glioblastoma growth, suggesting a new therapeutic strategy for glioblastoma.


  • Open Access

    Identification of hypoxic macrophages in glioblastoma: Unveiling therapeutic insights from tumour microenvironment analysis

    by Zhen Qin, Xiu‐Wu Bian, Yu Shi

    Tumor‐associatedmacrophages (TAMs) exhibit remarkable heterogeneity in glioblastoma. Spatially resolved single‐cell transcriptomic studies identified a monocyte‐derived TAM subset localized in the peri‐necrotic niche, driven by hypoxic cues to acquire ahypoxia response signature. These hypoxia‐TAMs destabilize endothelial adherens junctions through adrenomedullin paracrine signaling, promoting the formation of hyperpermeable neovasculature that impedes drug delivery. Blocking adrenomedullin produced by hypoxia‐TAMs restores vascular integrity, increases drug deliveryinto tumors, and provides combinatorial therapeutic benefits. Here we discuss the heterogeneity of TAMs regarding functional states and locations in glioblastomas, and propose future directions for studying the temporospatial dynamics of multifaceted TAM.Highlights: Single‐cell omics reveal a functionally and spatially distinct hypoxia‐TAM subset in glioblastoma. Adrenomedullin secreted by hypoxia‐TAM destabilizes tumor vasculature and its blockade enhances vessel integrity and drug delivery.


  • Top Cited Papers
    Open Access

    Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization

    by Wenying Wang, Tianran Li, Yue Cheng, Fei Li, Shuhong Qi, Min Mao, Jingjing Wu, Qing Liu, Xiaoning Zhang, Xuegang Li, et al.